These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 29360538)

  • 21. G1-checkpoint function including a cyclin-dependent kinase 2 regulatory pathway as potential determinant of 7-hydroxystaurosporine (UCN-01)-induced apoptosis and G1-phase accumulation.
    Akiyama T; Sugiyama K; Shimizu M; Tamaoki T; Akinaga S
    Jpn J Cancer Res; 1999 Dec; 90(12):1364-72. PubMed ID: 10665655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell cycle-related kinase in carcinogenesis.
    Tian Y; Wan H; Tan G
    Oncol Lett; 2012 Oct; 4(4):601-606. PubMed ID: 23205069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.
    Gomatou G; Trontzas I; Ioannou S; Drizou M; Syrigos N; Kotteas E
    Mol Biol Rep; 2021 Jan; 48(1):915-925. PubMed ID: 33409716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 27. BROMI/TBC1D32 together with CCRK/CDK20 and FAM149B1/JBTS36 contributes to intraflagellar transport turnaround involving ICK/CILK1.
    Satoda Y; Noguchi T; Fujii T; Taniguchi A; Katoh Y; Nakayama K
    Mol Biol Cell; 2022 Aug; 33(9):ar79. PubMed ID: 35609210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cell cycle-related kinase is a crucial regulator for ciliogenesis and Hedgehog signaling in embryonic mouse lung development.
    Lee H; Ko HW
    BMB Rep; 2020 Jul; 53(7):367-372. PubMed ID: 32317081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
    Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TGF-β/activin signaling promotes CDK7 inhibitor resistance in triple-negative breast cancer cells through upregulation of multidrug transporters.
    Webb BM; Bryson BL; Williams-Medina E; Bobbitt JR; Seachrist DD; Anstine LJ; Keri RA
    J Biol Chem; 2021 Oct; 297(4):101162. PubMed ID: 34481843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signal transducer and activator of transcription 3 cooperates with androgen receptor/cell cycle-related kinase signalling pathway in the progression of hepatitis B virus infection and gender differences.
    Xu Y; Qi W; Wang X; Zhang Y; Han L; Shi J; Wang G; Liu J; Duan H; Cong X; Zhao P; Zhou C; Wang J
    J Viral Hepat; 2022 Jul; 29(7):569-578. PubMed ID: 35567395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation.
    Baldassarre G; Barone MV; Belletti B; Sandomenico C; Bruni P; Spiezia S; Boccia A; Vento MT; Romano A; Pepe S; Fusco A; Viglietto G
    Oncogene; 1999 Nov; 18(46):6241-51. PubMed ID: 10597222
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P16Ink4a tumor suppressor function in lung cancer cells involves cyclin-dependent kinase 2 inhibition by Cip/Kip protein redistribution.
    Grimison B; Langan TA; Sclafani RA
    Cell Growth Differ; 2000 Oct; 11(10):507-15. PubMed ID: 11063124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting tumor-associated immune suppression with selective protein kinase A type I (PKAI) inhibitors may enhance cancer immunotherapy.
    Hussain M; Shah Z; Abbas N; Javeed A; Mukhtar MM; Zhang J
    Med Hypotheses; 2016 Jan; 86():56-9. PubMed ID: 26804598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MAPRE1 promotes cell cycle progression of hepatocellular carcinoma cells by interacting with CDK2.
    Liang XH; Feng ZP; Liu FQ; Yan R; Yin LY; Shen H; Lu HL
    Cell Biol Int; 2020 Nov; 44(11):2326-2333. PubMed ID: 32770827
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modified Biejia Jianwan decoction restrains PD-L1-mediated immune evasion through the HIF-1α/STAT3/NF-κB signaling pathway.
    Tian X; Liu F; Wang Z; Zhang J; Liu Q; Zhang Y; Zhang D; Huang C; Zhao J; Jiang S
    J Ethnopharmacol; 2024 Mar; 322():117577. PubMed ID: 38104877
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines.
    Eguchi T; Itadani H; Shimomura T; Kawanishi N; Hirai H; Kotani H
    Mol Cancer Ther; 2009 Jun; 8(6):1460-72. PubMed ID: 19509251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small-molecule cyclin-dependent kinase modulators.
    Senderowicz AM
    Oncogene; 2003 Sep; 22(42):6609-20. PubMed ID: 14528286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.